Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study.
about
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment.Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis.Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implicationsThe specialist physician's approach to rheumatoid arthritis in South AfricaCXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritisThe cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasionThe vitamin D receptor regulates rheumatoid arthritis synovial fibroblast invasion and morphologyComparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.Time to achieve remission determines time to be in remission.The arthritis severity locus Cia5a regulates the expression of inflammatory mediators including Syk pathway genes and proteases in pristane-induced arthritis.Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis.American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.Increased synovial expression of nuclear receptors correlates with protection in pristane-induced arthritis: a possible novel genetically regulated homeostatic mechanism.Sex: a major predictor of remission in early rheumatoid arthritis?Radiological damage in patients with rheumatoid arthritis on sustained remission.Identification of two new arthritis severity loci that regulate levels of autoantibodies, interleukin-1β, and joint damage in pristane- and collagen-induced arthritisGreater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registryLiver X receptor regulates rheumatoid arthritis fibroblast-like synoviocyte invasiveness, matrix metalloproteinase 2 activation, interleukin-6 and CXCL10.Periarticular osteoporosis is a prominent feature in early rheumatoid arthritis: estimation using shaft to periarticular bone mineral density ratioRecently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry.Preliminary study for predicting better methotrexate efficacy in Japanese patients with rheumatoid arthritis.Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register.Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexateA pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort.Patient-reported outcomes as predictors of remission in early rheumatoid arthritis patients treated with tight control treat-to-target approach.Predictors of remission, erosive disease and radiographic progression in a Colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study.Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy.The contribution of four immunogenetic markers for predicting persistent activity in patients with recent-onset rheumatoid arthritis or undifferentiated arthritisResponse to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis.Increased expression of proto-oncogene survivin predicts Joint destruction and persistent disease activity in early rheumatoid arthritis.The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years.Clinical courses and predictors of outcomes in patients with monoarthritis: a retrospective study of 171 cases.The good EULAR response at the first year is strongly predictive of clinical remission in rheumatoid arthritis: results from the TARAC cohort.Baseline HAQ and SF-36 questionnaire scores cannot predict clinical remission, radiographic progression or the need for biological therapy in a three-year prospective study of a Brazilian early rheumatoid arthritis cohort.Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice.Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS
P2860
Q24812386-686A8A6E-12CE-4158-9F06-6895197ADFD3Q24816803-D4DDCA8E-5004-4925-AE1B-007F05E0E672Q26738960-9249595A-16F0-4AFC-BBBA-13882BDB9A34Q26765122-1D0E6E5C-3A5B-4FD6-A98E-6C553B0F263CQ28569526-451C0281-B681-43F9-A133-C264835F46B0Q28573570-440ECDE4-C3E4-40CF-9CBB-D079335E6F33Q28577203-9AF9D87F-4AAD-4326-B879-6F41623BB246Q30727631-999462B6-68BC-49F3-9149-A02A271DD43AQ34027517-708E31CC-F331-4C03-AE8D-C4B7AE2AB37FQ34515149-2C90DC90-99E4-435C-9EC1-B77C82D0DB94Q34559803-9DC36596-2AC7-45C1-85C3-47B13F7EE644Q34580608-C65356FD-F8F8-44EB-90FA-F49E6970550DQ35047250-541B06AE-DD84-4F34-ABC9-E5233610BF46Q35243488-877678A0-AF3F-417A-98E9-8692CA0647E6Q35638333-9F7E735A-CDB6-4B31-A315-98764DABE02AQ35759974-CD3CC259-6463-4C56-B500-FC5917D8EE63Q35784822-D68F637E-B3BE-4E9E-B171-75048508986DQ36024297-91F5D131-013B-4B48-8FD3-B7AFD555C05EQ36283431-732E089C-3764-4414-9E10-BC77BF91744DQ36589519-6D434429-C7CB-4F8A-93AD-C3A7792DAFBFQ36670140-59C186DE-B624-4E80-8ECF-1E6A6809FEA1Q36975907-B10377FB-AA47-49A2-B28C-F1569461823AQ37195347-BE2E3FE7-82D1-4E63-9C85-C84EB0A37A5EQ37358983-26FEAE20-7520-49E6-812F-AAF07455AB2EQ37546519-2C407F17-66D6-44DD-8152-460683F1A091Q38185644-2FB02087-F70C-429E-B84D-2E1491C34833Q38910063-11AA0284-4569-4770-971A-416668780010Q39866800-28F2C8D5-DF88-45BF-A1A8-48839C7E69E7Q39902282-EEAA2778-0C80-42E9-9D05-FB1436F8563CQ40586509-6A153316-C3A2-4897-8599-A745B62D5E0AQ41931049-B9386D28-7C3F-4CF9-94CE-AC28F6DD7B21Q43187116-F1549E35-F555-4830-B19D-871F51744776Q44972131-6D9442C7-A884-4FBA-809C-A39B7287B2DEQ45958842-73B874E1-1533-4D16-B69F-5AF91B091780Q46081724-E095CAA9-324F-40C3-8D12-B7BC4597D4CBQ48511585-24028A80-90E8-459D-ABA7-588C333A4E3FQ48517263-CE91D8C0-BE69-407C-8B72-5373F3A41EE0Q58220963-E38B4E9C-0338-4FCC-8C65-2BAEAFBD6201
P2860
Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Prognostic factors for remissi ...... tiparameter prospective study.
@ast
Prognostic factors for remissi ...... tiparameter prospective study.
@en
type
label
Prognostic factors for remissi ...... tiparameter prospective study.
@ast
Prognostic factors for remissi ...... tiparameter prospective study.
@en
prefLabel
Prognostic factors for remissi ...... tiparameter prospective study.
@ast
Prognostic factors for remissi ...... tiparameter prospective study.
@en
P2093
P2860
P356
P1476
Prognostic factors for remissi ...... tiparameter prospective study.
@en
P2093
Cantagrel A
Dougados M
Goupille P
P2860
P304
P356
10.1136/ARD.2003.010611
P407
P577
2004-06-01T00:00:00Z